420 with CNW — Feds Seek Vendor to Test for Cannabis Compounds in Users’ Breath

As more states legalize medical and recreational cannabis use, law enforcement and opponents of cannabis reform argue that marijuana legalization will lead to increased rates of cannabis-impaired driving and traffic incidents. But while police officers can easily test for alcohol impairment using breathalyzer tests, there are currently no standardized tests to check for THC impairment via the breath.

Furthermore, research has uncovered that THC blood levels are not a reliable indicator of intoxication and impairment levels. Studies have found that the base THC blood level of long-term cannabis users can be higher than the legal limit set in several states. THC can also remain in the blood for hours after consumption and indicate impairment long after its effects have faded.

As such, authorities have been interested in developing technology that would allow police officers to accurately test for THC impairment onsite. The federal government plans on investing more than $1.4 million in studies designed to determine how the concentration of cannabis compounds changes in people’s breath over time after they consume cannabis.

The National Institute of Standards and Technology (NIST) recently posted a “sources sought,” stating that it is searching for a vendor that is able to help run a study that would collect blood and breath samples and then test those samples for evidence of acute cannabis use by checking for cannabinoids such as delta-9 THC and their metabolites.

NIST acting director of media relations Richard Press says that the nonregulatory agency is looking for a contractor that will recruit study participants, collect breath samples after the participants consume their own state-legal marijuana and then send the samples to NIST laboratories for analysis. He said that the purpose of the sources sought notice was to notify potential contractors of the study requirements.

Over the past decade, researchers have tried to develop machinery that would allow them to test for THC impairment the way breathalyzers test for alcohol. However, the industry hasn’t been able to develop an efficient standard testing method for cannabis impairment. With dozens of states now allowing cannabis consumption, the need for a standard device that can test for cannabis impairment has grown.

Titled Breath Measurements of Acute Cannabis Elimination (BACE), the upcoming study will research how the cannabinoid concentration in a person’s breath changes hours after they consume cannabis, Press says. The study’s objective will be to determine whether or not THC can remain in cannabis users’ breath even after they abstain for long periods.

The entire cannabis industry, including entities such as Flora Growth Corp. (NASDAQ: FLGC), would support a reliable way to detect impaired drivers, so the effort by NIST to study this matter is a welcome one.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Illinois Legislator to File Bill Centralizing Marijuana Regulation

Many people say the legal marijuana industry in Illinois has complex regulations and that there is room for politics to interfere with the process of licensing businesses. The possibility of litigation against the licensing system is also high, and some are calling for the establishment of a commission to streamline the regulatory process.

One of the people thinking this way is Rep. Marcus Evans, a Democratic lawmaker from Chicago. He revealed that he is planning to table a bill that will create a cannabis commission similar to the commissions governing the gaming and alcohol industries. Evans is irked by the numerous state agencies that applicants have to reach out to in their bid to obtain a license. Each step of this lengthy process involves the payment of fees, and these can quickly add up. He says matters are worse for social equity applicants who have even more steps to follow before they get the nod to participate in the legal marijuana industry in the state.

Evans also says creating a cannabis commission will save time and reduce the confusion surrounding the myriad state agencies with which applicants have to engage. He says he requires the help of a flow chart when explaining to people the process of getting a business licensed.

Pam Althoff, executive director of the Cannabis Association of Illinois, agrees. She wants to see the regulatory process streamlined so that people don’t have to contact different agencies, each of which plays a minor role in the licensing process. Some of the departments that applicants have to interface with include public health, revenue, agriculture, police and others.

Evans’ plan is to table a bill that will see the creation of a commission having seven individuals, including an executive director who will be a full-time employee. Other members would be representatives selected by the leaders of the state assembly along with gubernatorial appointees. The lawmaker believes that such a commission will bring stability to the work of regulating the marijuana industry and that future political interference in the licensing process will be forestalled, especially when new leaders who aren’t keen on a legal marijuana industry take office.

Cannabis sales are booming in the state, with records showing that a hefty $1.5 billion was generated as total sales during the 2021–2022 fiscal year. From this amount, $445 million went to the state coffers in the form of taxes and fees. These tax dollars are distributed according to a predetermined formula. For example, 25% goes to grants issued to organizations working in the communities that bore the brunt of the drug war while 8% is earmarked for supporting law enforcement efforts in the state.

It is such a progressive approach to overseeing the marijuana industry that will create enabling conditions for multistate cannabis operators such as American Cannabis Partners to thrive in the different markets that they set up shop in.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

The New York Cannabis and Hemp Convention to Boost the Growing Local Markets

Businesses, entrepreneurs, advocates, patients, investors, educators, and consumers, are invited to attend the NECANN Convention, a physical event being held in Albany, New York on August 26-27, 2022.

NECANN has been producing popular and influential events to local communities throughout the northeast and beyond since 2014, shaping the developing cannabis economy by creating an important hub of resources and communication focused on local markets. NECANN events attract a huge number of hemp, MMJ, and cannabis industry professionals in the Northeast, and represent a home base for the New England cannabis industry.

The New England Cannabis Convention offers a wonderful opportunity for the local community to grow and prosper. There are robust networking, communication, and business opportunities for cannabis cultivators, consumers, and business vendors across the region. The convention brings together the local cannabis community and fosters interactive trade and communication. New and established businesses, cannabis growers, and dealers, can discover business prospects and connect with top cannabis companies and investors. For budding entrepreneurs, it’s a wonderful forum that offers the opportunity to learn the latest industry trends in cannabis cultivation and trading.

Touted as the key event for cannabis businesses on the East Coast, NECANN events are considered one of the best organized for the cannabis community, professionally run by a highly experienced team that devotes months of planning and research to put the event together. While these events offer phenomenal networking and informational opportunities, participants also enjoy numerous amenities in a fun environment.

Cannabis experts throughout the region will share insights and their knowledge with a wide cannabis audience through vending, guest speaking, and interactive sessions at NECANN New York. The event is attended by industry stalwarts and thought leaders who will discuss business strategies and the future trends of this growing industry. They will also throw light on the latest products and technologies specifically oriented to the local cannabis community. Businesses looking to pitch their products and services should make contact as soon as possible through the link below.

To learn more, please visit https://necann.com/new-york-convention/.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Inches Closer to DehydraTECH-CBD FDA Evaluation Following Successful Dosing in Multi-Week HYPER-H21-4 Human Clinical Study

Lexaria just completed dosing for its HYPER H21-4 human clinical study that dosed 64 patients aged between 40 and 70 with measured elevated blood pressure, stage 1 and stage 2 hypertension
HYPER-H21-4, Lexaria’s most ambitious hypertension clinical study yet, builds on the success of HYPER-H21-1 and HYPER-H21-2, both completed in 2021
It explores the use of the company’s patented DehydraTECH(TM) technology in the potential treatment of hypertension
Lexaria is confident that the additional data sets collected over the course of the study will lead to supplementary applications for DehydraTECH while providing valuable additional insights into the long-term health benefits of this compound that might otherwise remain undetected

In November 2021, Lexaria Bioscience (NASDAQ: LEXX) announced its most ambitious hypertension study yet, HYPER-H21-4. The goal of the study, according to Lexaria’s Chief Executive Officer (“CEO”), Chris Bunka, was to “Support the company’s goals related to pursuit of regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure,” (https://cnw.fm/8fXrT).

At the close of the year, Lexaria received independent Review Board (“IRB”) approval ahead of schedule, which marked a significant milestone for the company. It would set the stage for the commencement of the study in the year 2022 while allowing Lexaria to explore the full potential of its patented DehydraTECH(TM) technology in hypertension treatment (https://cnw.fm/Ozbsy).

On July 27, 2022, Lexaria announced that dosing with DehydraTECH-processed cannabidiol (“DehydraTECH-CBD”) had been completed in a multi-week human clinical hypertension study. Most notably, no serious adverse events were reported due to the dosing: the absence of serious adverse events is a critical goal of typical Phase I and Phase II FDA-registered studies Furthermore, the whole undertaking was completed on schedule, another huge milestone for the company as it works towards enhancing its understanding of DehydraTECH-CBD and its effectiveness in treating cardiovascular and other disease states beyond hypertension (https://cnw.fm/EWmEf).

“We are extremely pleased that dosing has been completed on time in this multi-week clinical study without any serious adverse events having occurred,” noted Mr. Bunka.

“Demonstrating a noteworthy safety and tolerability profile relative to conventional anti-hypertensive medications is one of Lexaria’s major goals with this program, and avoiding serious adverse events at clinically efficacious doses will be a primary requirement to achieve eventual regulatory marketing authorizations,” he added.

This HYPER-H21-4 study consisted of male and female volunteers aged between 40 and 70. These volunteers had documented or measured elevated blood pressure, mild (stage 1) hypertension, to moderate (stage 2) hypertension. They received DehydraTECH-CBD every day for five weeks, with the doses escalating between 225 mg/day to 450 mg/day over the study duration, adjusted relative to body weight.

The study’s extended duration allowed Lexaria to collect critical data monitoring the safety and efficacy of its DehydraTECH-CBD over time. This allowed the company to evaluate the potential for longer health benefits. Some of the study outcomes include vascular health, incorporating arterial stiffness and autonomic balance, electrocardiogram (“ECG”) analysis, brain structure and function through MRI testing, and blood biomarkers, among others.

Lexaria is confident that each of these data sets will lead to additional applications for DehydraTECH-CBD while also providing valuable additional insights into the long-term health benefits of this compound that might otherwise remain undetected. Analysis of most of the data collected since the beginning of the study has begun and results should begin to be released in September 2022, with additional results to be release subsequently.

HYPER-H21-4 builds on HYPER-H21-1 and HYPER-H21-2 studies, all conducted in 2021. Both of these previous studies evidenced a rapid and sustained drop in blood pressure with DehydraTECH-CBD in what Mr. Bunka described as “encouraging early results.” As a result, Lexaria is optimistic that with the success of its latest study, its DehydraTECH-CBD will offer a better alternative to existing hypertension drugs in the market, mostly known for their unwanted side effects once approved.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Why Marijuana Retailers Need to Look Beyond THC Concentration

Most cannabis buyers have only the THC concentration in mind when they are choosing a marijuana product, but hasn’t the time come for retailers to look beyond how much THC a given product contains while making a decision about its quality?

Until recently, marijuana was illegal, but dozens of U.S. states have since legalized it either for medical or recreational use. One strong reason for outlawing marijuana was its psychoactive compound THC, which is why most tests look for THC metabolites in the blood, urine and even hair samples.

It is therefore understandable that people will focus on potency (THC concentration) when choosing a product to buy. In the eyes of consumers, more THC equals a promise of a better experience. Or does it?

Buyers are beginning to appreciate that high THC concentrations aren’t for everyone. For example, newbies to smoking cannabis can be spooked when they consume marijuana with THC that is stronger than 25% since it may quickly trigger psychoactive effects. Additionally, some marijuana users prefer a chilled kind of high, and high THC numbers cannot give them what they seek.

The space is beginning to see a growing body of discerning cannabis users who look beyond THC concentration when evaluating the desirability of a given marijuana product. These buyers want to know the flavonoids, terpenes and minor cannabinoids (such as CBG and CBN) present in a product so that they can judge whether that product will give them the experience they are looking for.

This growing sophistication is what marijuana retailers should be working to capitalize on as the nascent industry matures. This is how brands can stand out instead of remaining stuck in the THC concentration battle with every player in the industry.

For starters, manufacturers need to improve their labels to reflect all the compounds present in a given product. Many states only require the amount of THC in a product to be indicated on the label, but future-minded companies can go beyond this basic requirement and outline all compounds available in the product. Remember, the entourage effect is pivotal to one’s experience, so the obsession with THC concentration misses a vital opportunity to stand out.

Budtenders are at the frontline when it comes to getting cannabis products to customers. These professionals need to be adequately trained so that they can educate customers about how, for example, a given terpene combination plus THC of a certain level would be best for meeting certain needs of buyers. Companies can nurture customer loyalty when they adopt this approach, and they can also cement their uniqueness in the industry.

The growing customer sophistication is also creating market for ancillary products such as the grow pods made by Advanced Container Technologies Inc. (OTC: ACTX). Before long, mass-produced cannabis products will be competing with homegrown ones as people opt to take matters into their own hands in jurisdictions where this is allowed.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Las Vegas Awaits Launch of Marijuana Consumption Lounges

Although they are a relatively new concept, marijuana consumption lounges are probably the most controversial aspect of the entire cannabis reform movement. The idea is to provide public rooms where customers can consume cannabis without running afoul of state cannabis laws. While more than a dozen states have now legalized recreational cannabis consumption, they have also outlawed public consumption and made it almost impossible for nonresidents to legally consume the cannabis they have purchased.

New York was among the first states to allow cannabis consumption sites for adults aged 21 and over. The state recently passed a bill that would allow licensed businesses to sell cannabis products and provide a space for customers to consume the cannabis they bought on site.

Just a few months later, Las Vegas is poised to launch its first marijuana consumption site as well, becoming the second state in the country to legalize the operation of consumption lounges. Regulators from Nevada recently finalized regulations for the state’s cannabis market that would lead to the opening of an estimated 60 to 65 marijuana consumption lounges. The move was aimed at making the state more attractive to tourists and boosting cannabis tourism, a segment that is now estimated to be worth $17 billion.

According to a public statement from the Cannabis Compliance Board, the first consumption sites are slated to open before the end of the year. The state of Nevada will issue some 40 to 45 licenses to existing cannabis stores as well as 20 licenses to independent consumption lounges. Another 10 licenses will be issued to social-equity applicants, people who live in disadvantaged areas, or people with prior nonviolent cannabis convictions.

The social equity licenses will have discounted fees. As per the finalized regulations, regulators will begin processing consumption lounge licenses starting this fall.

Nearly 65 applicants have already expressed interest in receiving the consumption lounge licenses, and they have even begun leveraging strategies to help the businesses stay profitable in the new cannabis-consumption-lounge segment.

This includes providing calm, comfortable spaces to act as an alternative to the Strip’s boisterous nightclub atmosphere and taking advantage of the consumption lounge to drive customer traffic to adjacent businesses. Cannabis tourism is a massive segment, says Christopher LaPorte, founder of marijuana hospitality firm Reset Vegas. LaPorte sees Las Vegas becoming a major marijuana tourism destination. Planet 13, a large entertainment center and dispensary near the Strip, is also looking to enter the consumption lounge segment by combining the lounge and restaurant experience.

It is steps like these in the development of the cannabis industry that show companies such as Prime Harvest Inc. that there is significant potential growth and opportunities in the industry if enabling laws and systems are put in place.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Advanced Container Technologies Inc. (ACTX) Establishing Foothold in Growing Billion-Dollar Vertical Farming Space

Vertical farming projected to reach more than $25 billion by 2030, with a CAGR of 23.3%
MRFR report notes that “vertical farming systems and technologies offer a superior approach to farming methods”
ACTX GrowPods are essentially vertical micro-farms that can be placed anywhere, allow cultivation of a wide variety of crops, 365 days a year

A recent Market Research Future (“MRFR”) report shows that vertical farming is projected to reach more than $25 billion by 2030, with a CAGR of 23.3% (https://cnw.fm/kKdVm). Those numbers bode well for Advanced Container Technologies (OTC: ACTX), a company in the business of selling GrowPods, self-contained, automated, indoor “micro-farms” that are building a reputation in the vertical farming space.

“Vertical farming systems and technologies offer a superior approach to farming methods, allowing for the growing of large amounts of crops inside a confined land area while requiring little financial investment and having no negative impact on the environment,” reported MRFR’s comprehensive research report. “The main reason for this is because perpendicular stack-based farming lowers the need for additional land and allows for full land utilization for farming, with optimal land and energy use yielding significant returns. The vertical farming market has seen diversified growth in all segments and across different regions as a result of rising populations and rising per capita incomes, which has shifted people’s demands toward more organic, health, and environment-friendly foodstuffs, resulting in the development of the vertical farming market.”

The report also noted that consumers are more aware of what they are eating and are prioritizing health. These changes have “fueled the market for organic farming, which produces fruits and vegetables that are free of insecticides and pesticides and high in nutritional content,” the report continued. “The desire for organic and high-quality foods has transformed vertical farming firms’ production capabilities and created a foundation for ensuring high-quality and quantity-approved production to fulfill rising needs. In addition, people have begun to cultivate fruits and vegetables indoors, giving rise to the concept of indoor vertical farming.”

Advanced Container Technologies is keenly aware of the opportunities in vertical farming and appears uniquely suited for growth in the space. The company is the sole distributor of GrowPods, which are advanced, self-contained hydroponic containers manufactured by GP Solutions Inc.

“These innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year,” states the company. “Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.”

In addition to selling and distributing GrowPods, Advanced Container Technologies offers related equipment and supplies. Additionally, the company designs and sells patented, proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

For more information, visit the company’s website at www.AdvancedContainerTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://cnw.fm/ACTX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Largest Employee Union Wants End to Testing Federal Employees for THC

For decades, federal employers have had the right to test their employees for cannabis used because of federal regulations that outlawed the cultivation, distribution and sale of marijuana. But as states have begun to legalize recreational and medical cannabis use, reform activists argued that these drug tests penalize consumers for indulging in behaviors that are considered legal in their home states.

The largest federal employee union in the country is now calling on the government to put an end to policies that punish federal workers for using cannabis during their free time. The American Federation of Government Employees (AFGE) also adopted a resolution in support of federal cannabis legalization during its 42nd national convention last month. AFGE currently represents more than 700,000 federal workers in America.

Although the union hasn’t released the final text of the measure, which is titled “Resolution to Support Deleting Responsible Off-Duty Marijuana Usage from Sustainability Criteria,” it posted the resolution on its website. According to a draft version of the measure that was obtained by Marijuana Moment, it also supports the Marijuana Opportunity, Reinvestment and Expungement (MORE) Act.

If it becomes law, the MORE Act would remove cannabis from the list of controlled substances, eliminate penalties for federal cannabis offenses and expunge prior federal cannabis convictions from people’s records. It has advanced past the House of Representatives twice so far.

The resolution noted that cannabis use has been increasingly accepted by the American public, especially regarding cannabis use for medical purposes by veterans and civilians. This is clear by the number of states that have chosen to legalize cannabis for medical use in recent years. However, cannabis remains a controlled substance at the federal level, and the resolution says this attaches unreasonable security to cannabis usage.

As such, members of AFGE voted in favor of the measure to partner with other unions and support federal cannabis legalization as well as compel the U.S. Office of Personnel Management (OPM) to get rid of federal policies that require testing cannabis in employees who work in nonnational and nonsafety sensitive positions. AFGE requested that the OPM remove responsible off-duty cannabis use from its sustainability criteria 5 CFR § 731.202 at the state level in Washington, D.C., and other jurisdictions with medical marijuana programs.

The draft measure also urged the OPM to remove marijuana-related questions from the SF86, e-QIP, SF85 and SF8SP. These are some of the forms that people applying for certain federal government positions have to fill out. The measure came shortly after the leaders of the House Appropriations Committee urged the White House to review guidelines and policies on the firing and hiring of individuals who use cannabis privately in states with legal markets.

If these reforms are implemented, more people will feel free to try out the cannabis products made by state-legal companies such as Flora Growth Corp. (NASDAQ: FLGC) since the fear of being victimized or even losing their federal jobs would have been removed.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — New Research Finds Legalization Hasn’t Increased Number of Teens Trying Cannabis

Concerns around how the legalization of marijuana for adult use may prompt an increase in the number of young users have been floated by both parents and health researchers since talks on legalization began a decade ago. Critics against the policy change have even gone as far as to issue warnings with no evidence to back the claims. However, new research has found that the legalization of marijuana does not cause more young individuals to try using the substance.

The study, which was conducted by researchers at Michigan State University, found that legalized marijuana retail sales did not increase the number of underage individuals who consumed cannabis. The researchers cited existing studies on the use of alcohol among the youth to highlight the importance between prevalence and incidence. Research from 2016 and 2018 shows that a big proportion of youth in the United States did not drink alcohol until they could legally. The researchers theorized that the same trend could be true with marijuana.

For their study, the researchers used public data of individuals aged between 12 and 20, then those aged 21 and above, obtained from the National Survey on Drug Use and Health. They analyzed the data using the event study model in an attempt to evaluate the causal effect legalization had on marijuana use. This is in addition to projecting levels of cannabis use if legalization hadn’t been enacted.

They discovered that legalizing adult-use marijuana did increase first-time marijuana consumption — but only among individuals who could use the drug legally once the policy change was enacted. In their report, the researchers noted that they observed no evidence of an increase in use among underage individuals.

The lead author of the study, Barrett Wallace Montgomery, stated that by contrast, the number of individuals aged 21 and above who were trying marijuana for the first time after adult-use legalization could double or triple.

NORML, a marijuana advocacy group, stated in a recent blog post that the study’s findings were consistent with previous research, which had shown that adult-use legalization wasn’t linked to increased access or use among young individuals.

The study was partly funded by the National Institutes of Health and its findings were published in the “PLOS One” journal. The study claims to be the first one designed to assess incidence of use as a result of the legalization of adult-use cannabis. Prior studies have centered on prevalence, trying to measure the effect legalization has had on how much marijuana individuals use or how often they use it.

Marijuana industry actors such as Cannabis Strategic Ventures Inc. (OTC: NUGS) will be pleased to see that independent studies are confirming what they knew all along —rather than increasing underage access, creating legal markets would limit how easy it is for youth to get their hands on marijuana.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND Program

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of a positive full written response from the Food and Drug Administration (“FDA”) from its pre-Investigational New Drug (“Pre-IND”) meeting regarding DehydraTECH-CBD for the treatment of hypertension. According to the update, the FDA confirmed agreement with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway for its program. This is advantageous because the abbreviated pathway, as it is often described, typically enables a faster route to commercial approval than the traditional 505(b)(1) NDA pathway. “We are very pleased to have received comments from the FDA toward opening our IND program and we will be executing FDA-confirmed IND-enabling work immediately,” said John Docherty, president of Lexaria Bioscience Corp. “We were delighted that our proposals were very well received by the FDA and the feedback received will be very helpful in compiling and filing our IND application as the next major regulatory step we are focused on moving forward.”

To view the full press release, visit https://cnw.fm/GpHx1

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 26 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.